ADIPOQ and metabolic dysfunction-associated steatotic liver disease: The adipose tissue dysfunction, characterized by a dysregulated response of adiponectin to fat metabolism and ingestion has been shown to modulate liver injury and cardiometabolic risk in NAFLD (117).